FCGR3A and cancer: Recently, an innovative fit-for-purpose redirected optimized cell killing (ROCK®) platform has been developed to generate an array of bispecific tetravalent CD16A-binding antibodies, the so-called innate cell engager (ICE®, Affimed GmbH, Heidelberg, Germany) constructs, aiming to maximize the potential of NK cells and macrophages in targeting cancer cells [24].